Jing Du, MD, PhD
she/her/hers
Instructor of Medicine (Medical Oncology)DownloadHi-Res Photo
Cards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAbout
Titles
Instructor of Medicine (Medical Oncology)
Biography
Jing Du, MD, PhD, is an Instructor of Medicine (Medical Oncology), and cares for patients with breast cancer at Smilow Cancer Hospital in New Haven. She received her medical degree from the Shanghai Jiao Tong University School of Medicine, and completed her PhD in Biochemistry at the University of South Carolina. She then pursued a Kirschstein-NRSA Training Fellowship in the lab of Dr. John Hwa at Yale School of Medicine. Dr. Du finished her residency training with Yale New Haven Health where she received the prestigious Browning Award for outstanding dedication, commitment, and professionalism. She completed her fellowship in Medical Oncology-Hematology at Yale School of Medicine.
Dr. Du is the author of multiple peer-reviewed publications and is developing and leading investigator-initiated clinical trials as principal investigator that evaluate new interventions and therapies in order to expand mechanistic-based treatment options. She collaborates with translational labs to investigate the tumor microenvironment and discover new biomarkers and potential novel therapeutic strategies through cutting-edge spatial multi-omics techniques. She is dedicated to conducting impactful clinical research that effectively bridges the gap between laboratory breakthroughs and clinical applications, aiming to mitigate treatment toxicities and improve patient outcomes.
Appointments
Medical Oncology
InstructorPrimary
Other Departments & Organizations
- Center for Breast Cancer
- Developmental Therapeutics
- Internal Medicine
- Medical Oncology
- Yale Cancer Center
- Yale Medicine
Education & Training
- Fellowship
- Yale University Yale New Haven Hospital
- Resident
- Yale University Greenwich Hospital
- Intern
- Yale University Greenwich Hospital
- PhD
- University of South Carolina, Biochemistry
- MD
- Shanghai Jiao Tong University School of Medicine
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Jing Du's published research.
Publications Timeline
A big-picture view of Jing Du's research output by year.
John Hwa, MD, PhD, FRACP
Kanika Jain, PhD
Tarun Tyagi, PhD
Raimund Herzog, MD, MHS
John Kadado
Abhijit Patel, MD, PhD
10Publications
497Citations
Publications
2022
Platelet-derived TLT-1 promotes tumor progression by suppressing CD8+ T cells
Tyagi T, Jain K, Yarovinsky TO, Chiorazzi M, Du J, Castro C, Griffin J, Korde A, Martin KA, Takyar SS, Flavell RA, Patel AA, Hwa J. Platelet-derived TLT-1 promotes tumor progression by suppressing CD8+ T cells. Journal Of Experimental Medicine 2022, 220: e20212218. PMID: 36305874, PMCID: PMC9814191, DOI: 10.1084/jem.20212218.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCD8 T cellsT cellsTLT-1Non-small cell lung cancer patientsCell lung cancer patientsTREM-like transcript-1Tumor immunosuppressive mechanismsT cell suppressionLung cancer patientsPatient T cellsNF-ÎşB pathwayPatient-derived tumorsDistinct activation phenotypesNSCLC patientsImmunosuppressive mechanismsSyngeneic tumorsHumanized miceImmunoregulatory rolePrognostic significanceImmunocompetent miceCancer patientsCell suppressionActivation phenotypeReduced tumorTumor growthUnfolded Protein Response Differentially Modulates the Platelet Phenotype
Jain K, Tyagi T, Du J, Hu X, Patell K, Martin KA, Hwa J. Unfolded Protein Response Differentially Modulates the Platelet Phenotype. Circulation Research 2022, 131: 290-307. PMID: 35862006, PMCID: PMC9357223, DOI: 10.1161/circresaha.121.320530.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsUPR pathwayProtein responseMouse plateletsUnfolded protein responseActivation of UPRPlatelet phenotypeTranscriptional regulationGenomic regulationProtein misfoldingAnucleate plateletsProtein aggregationUPR activationPhosphorylation of PLCγ2Chemical chaperonesXBP1 pathwayP38 MAPKPERK pathwayUPRPKCδ activationPlatelet physiologyActivation pathwayPathwayPhenotypeIRE1α inhibitionSelective induction
2020
Parkin Coordinates Platelet Stress Response in Diabetes Mellitus: A Big Role in a Small Cell
Lee SH, Du J, Hwa J, Kim WH. Parkin Coordinates Platelet Stress Response in Diabetes Mellitus: A Big Role in a Small Cell. International Journal Of Molecular Sciences 2020, 21: 5869. PMID: 32824240, PMCID: PMC7461561, DOI: 10.3390/ijms21165869.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsMeSH Keywords14-3-3 ProteinsAnimalsBlood PlateletsCells, CulturedDiabetes MellitusHumansLysosome-Associated Membrane GlycoproteinsMiceMice, Inbred C57BLMitochondriaMitochondrial Trifunctional Protein, alpha SubunitMitophagyPlatelet ActivationProtein BindingProtein Serine-Threonine KinasesStress, PhysiologicalUbiquitin-Protein LigasesValosin Containing ProteinConceptsDiabetes mellitusDiabetic plateletsPlatelet activationNew potential therapeutic targetsEndogenous protective rolePotential therapeutic targetHealthy controlsMitochondrial β-oxidationPlatelet mitochondrial dysfunctionHealthy plateletsTherapeutic targetProtective rolePlatelet aggregationMitochondrial protectionMitochondrial dysfunctionMellitusPlateletsΒ-oxidationStress responseActivationParkinParkin-dependent mitophagyCellsDysfunctionTargeting lysosomes
2019
Mitochondrial MsrB2 serves as a switch and transducer for mitophagy
Lee SH, Lee S, Du J, Jain K, Ding M, Kadado AJ, Atteya G, Jaji Z, Tyagi T, Kim W, Herzog RI, Patel A, Ionescu CN, Martin KA, Hwa J. Mitochondrial MsrB2 serves as a switch and transducer for mitophagy. EMBO Molecular Medicine 2019, 11: emmm201910409. PMID: 31282614, PMCID: PMC6685081, DOI: 10.15252/emmm.201910409.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAnimalsBlood PlateletsCell LineDiabetes MellitusFemaleHumansMethionine Sulfoxide ReductasesMice, Inbred C57BLMice, KnockoutMicrofilament ProteinsMicrotubule-Associated ProteinsMitochondriaMitochondrial Membrane Transport ProteinsMitochondrial Permeability Transition PoreMitophagyMutationOxidation-ReductionOxidative StressParkinson DiseaseSignal TransductionUbiquitinationUbiquitin-Protein LigasesConceptsReduced mitophagyOxidative stress-induced mitophagyNovel regulatory mechanismStress-induced mitophagyLC3 interactionMitochondrial matrixDamaged mitochondriaMsrB2Reactive oxygen speciesRegulatory mechanismsMethionine oxidationMitophagyMitochondriaPlatelet apoptosisOxygen speciesPlatelet-specific knockoutApoptosisPathophysiological importanceExpressionImportant roleUbiquitinationParkin mutationsParkinSpeciesLC3Age associated non-linear regulation of redox homeostasis in the anucleate platelet: Implications for CVD risk patients
Jain K, Tyagi T, Patell K, Xie Y, Kadado AJ, Lee SH, Yarovinsky T, Du J, Hwang J, Martin KA, Testani J, Ionescu CN, Hwa J. Age associated non-linear regulation of redox homeostasis in the anucleate platelet: Implications for CVD risk patients. EBioMedicine 2019, 44: 28-40. PMID: 31130473, PMCID: PMC6604369, DOI: 10.1016/j.ebiom.2019.05.022.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdaptation, PhysiologicalAge FactorsAgedAged, 80 and overAgingAnimalsAntioxidantsApoptosisBiomarkersBlood PlateletsCardiovascular DiseasesComorbidityDisease Models, AnimalFemaleHomeostasisHumansMaleMiceMiddle AgedOxidation-ReductionOxidative StressPlatelet ActivationPlatelet AdhesivenessReactive Oxygen SpeciesRisk AssessmentRisk FactorsConceptsRisk patientsMouse studiesPlatelet phenotypeMajor adverse cardiovascular eventsHigh cardiovascular risk patientsAdaptive increaseAdverse cardiovascular eventsCentral pathophysiological roleCVD risk patientsCardiovascular risk patientsAggressive antiplatelet therapyEffect of comorbidityAge group 40Young healthy subjectsAntiplatelet therapyCardiovascular eventsYear age cohortAdvanced ageCVD patientsGroup 40Healthy subjectsPathophysiological roleElderly populationCardiovascular pathologyPatients
2018
Diabetes Exacerbates Myocardial Ischemia/Reperfusion Injury by Down-Regulation of MicroRNA and Up-Regulation of O-GlcNAcylation
Wang D, Hu X, Lee SH, Chen F, Jiang K, Tu Z, Liu Z, Du J, Wang L, Yin C, Liao Y, Shang H, Martin KA, Herzog RI, Young LH, Qian L, Hwa J, Xiang Y. Diabetes Exacerbates Myocardial Ischemia/Reperfusion Injury by Down-Regulation of MicroRNA and Up-Regulation of O-GlcNAcylation. JACC Basic To Translational Science 2018, 3: 350-362. PMID: 30062222, PMCID: PMC6058960, DOI: 10.1016/j.jacbts.2018.01.005.Peer-Reviewed Original ResearchCitationsAltmetricConceptsR injuryInfarct sizeMyocardial ischemia/reperfusion injuryIschemia/reperfusion injuryMyocardial ischemia/reperfusionMiR-24Ischemia/reperfusionMyocardial infarct sizePromising therapeutic candidateReperfusion injuryDiabetic heartMyocardial infarctionPoor survivalMouse modelTherapeutic candidateO-GlcNAcylationGenetic overexpressionUp-RegulationInjuryDown regulationMultiple key proteinsKey proteinsHeartReperfusionHyperglycemia
2017
Opposing Actions of AKT (Protein Kinase B) Isoforms in Vascular Smooth Muscle Injury and Therapeutic Response
Jin Y, Xie Y, Ostriker AC, Zhang X, Liu R, Lee MY, Leslie KL, Tang W, Du J, Lee SH, Wang Y, Sessa WC, Hwa J, Yu J, Martin KA. Opposing Actions of AKT (Protein Kinase B) Isoforms in Vascular Smooth Muscle Injury and Therapeutic Response. Arteriosclerosis Thrombosis And Vascular Biology 2017, 37: 2311-2321. PMID: 29025710, PMCID: PMC5699966, DOI: 10.1161/atvbaha.117.310053.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAnimalsBinding SitesCell Cycle ProteinsCell DifferentiationCell MovementCell ProliferationCells, CulturedDisease Models, AnimalForkhead Transcription FactorsGene Expression RegulationGenetic Predisposition to DiseaseHumansMice, KnockoutMuscle, Smooth, VascularMyocytes, Smooth MuscleNeointimaNuclear ProteinsPhenotypePromoter Regions, GeneticProto-Oncogene Proteins c-aktRNA InterferenceRNA, MessengerSignal TransductionSirolimusTime FactorsTrans-ActivatorsTranscription FactorsTransfectionVascular System InjuriesConceptsIntimal hyperplasiaTherapeutic inhibitionVascular smooth muscle injurySmooth muscle-specific deletionSmooth muscle cell proliferationSystemic vascular diseaseSevere intimal hyperplasiaSmooth muscle injuryNew treatment strategiesWild-type miceAkt isoformsMuscle cell proliferationMuscle-specific deletionMechanism of actionVascular smooth muscle cell differentiationCoronary revascularizationSmooth muscle cell differentiationDiabetes mellitusDiabetic patientsControl miceRapamycin therapyVascular diseaseMuscle injuryTherapeutic responseSevere thrombosis
2016
Inducing mitophagy in diabetic platelets protects against severe oxidative stress
Lee SH, Du J, Stitham J, Atteya G, Lee S, Xiang Y, Wang D, Jin Y, Leslie KL, Spollett G, Srivastava A, Mannam P, Ostriker A, Martin KA, Tang WH, Hwa J. Inducing mitophagy in diabetic platelets protects against severe oxidative stress. EMBO Molecular Medicine 2016, 8: 779-795. PMID: 27221050, PMCID: PMC4931291, DOI: 10.15252/emmm.201506046.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsDiabetes mellitusOxidative stressThrombotic cardiovascular eventsAnticipation of exposureCardiovascular eventsOxidative stress-mediated mitochondrial damageNormal platelet activationDiabetic plateletsPlatelet functionPlatelet pathologyPlatelet activationSevere oxidative stressNormal plateletsConsiderable mortalityProtective mechanismMitochondrial damageMellitusThrombosisPlateletsMitophagy inductionPhosphorylated p53Mitophagy machineryPlatelets resultsAutophagy processJNK activation
2015
Hyperglycemia repression of miR-24 coordinately upregulates endothelial cell expression and secretion of von Willebrand factor
Xiang Y, Cheng J, Wang D, Hu X, Xie Y, Stitham J, Atteya G, Du J, Tang WH, Lee SH, Leslie K, Spollett G, Liu Z, Herzog E, Herzog RI, Lu J, Martin KA, Hwa J. Hyperglycemia repression of miR-24 coordinately upregulates endothelial cell expression and secretion of von Willebrand factor. Blood 2015, 125: 3377-3387. PMID: 25814526, PMCID: PMC4447857, DOI: 10.1182/blood-2015-01-620278.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsVon Willebrand factorDiabetes mellitusMiR-24Diabetic patientsAdverse thrombotic eventsThrombotic cardiovascular eventsVWF expressionWillebrand factorDiabetic mouse modelNovel therapeutic targetHistamine H1 receptorsEndothelial cell expressionHyperglycemia-induced activationCardiovascular eventsThrombotic eventsH1 receptorsMouse modelVWF levelsTherapeutic targetCell expressionMellitusPatientsEndothelial cellsElevated levelsReactive oxygen species
2014
Aldose Reductase–Mediated Phosphorylation of p53 Leads to Mitochondrial Dysfunction and Damage in Diabetic Platelets
Tang WH, Stitham J, Jin Y, Liu R, Lee SH, Du J, Atteya G, Gleim S, Spollett G, Martin K, Hwa J. Aldose Reductase–Mediated Phosphorylation of p53 Leads to Mitochondrial Dysfunction and Damage in Diabetic Platelets. Circulation 2014, 129: 1598-1609. PMID: 24474649, PMCID: PMC3989377, DOI: 10.1161/circulationaha.113.005224.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdultAgedAldehyde ReductaseAnimalsApoptosisBcl-X ProteinBlood PlateletsCarotid Artery DiseasesDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2Disease Models, AnimalFemaleHumansMaleMiceMice, Inbred C57BLMice, KnockoutMiddle AgedMitochondrial DiseasesPhosphorylationSignal TransductionThrombosisTumor Suppressor Protein p53ConceptsMitochondrial dysfunctionHyperglycemia-induced mitochondrial dysfunctionP53 phosphorylationAntiapoptotic protein Bcl-xL.Platelet apoptosisMitochondrial damageMitochondrial membrane potentialReductase activationActivation of p53Reactive oxygen species productionOxygen species productionBcl-xL.Molecular pathwaysSevere mitochondrial damagePhosphorylationNovel therapeutic targetAldose reductase activationSpecies productionMembrane potentialApoptosisCentral roleTherapeutic targetDose-dependent mannerActivationP53
Clinical Trials
Current Trials
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
HIC ID2000037395RoleSub InvestigatorPrimary Completion Date07/11/2027Recruiting ParticipantsA Phase 2 Study of Alisertib in Combination with Endocrine Therapy in Patients with HR+, HER2-negative Recurrent or Metastatic Breast Cancer
HIC ID2000038098RoleSub InvestigatorPrimary Completion Date06/30/2027Recruiting Participants2000033529: A pilot study to evaluate biomarkers and safety of dapagliflozin concomitant with neoadjuvant therapy for patient with HER2-negative early-stage breast cancer and hyperinsulinemia (previously HIC 2000031461) [Yale HIC]
HIC ID2000033529RoleSub InvestigatorPrimary Completion Date12/31/2025Recruiting ParticipantsA Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
HIC ID2000037221RoleSub InvestigatorPrimary Completion Date09/01/2026Recruiting ParticipantsA Phase Ib/III, Open-label, Randomised Study of Capivasertib Plus CDK4/6 Inhibitors and Fulvestrant Versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)
HIC ID2000036257RoleSub InvestigatorPrimary Completion Date11/01/2027Recruiting Participants
Clinical Care
Overview
Clinical Specialties
Breast Oncology; Medical Oncology
Fact Sheets
Breast Cancer
Learn More on Yale MedicineCancer
Learn More on Yale MedicineDiagnosing Cancer
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
News
- July 24, 2024
Breast Medical Oncologist, Dr. Jing Du, Joins Smilow Cancer Hospital
- March 20, 2023
Unfolded Protein Response in Platelets and Diabetes
- January 11, 2023
Discoveries & Impact (January 2023)
Get In Touch
Contacts
Email
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.